婦人科領域のがん治療薬の世界市場

婦人科領域のがん治療薬の世界市場は2030年に215億米ドルに達する

COVID-19後の変化したビジネス環境において、2022年に144億米ドルと推定される婦人科領域のがん治療薬の世界市場は、2030年には215億米ドルに達すると予測され、2022年から2030年にかけてCAGR 5.2%で成長するとされています。本レポートで分析したセグメントの一つである標的療法は、CAGR5.6%を記録し、分析期間終了時には109億米ドルに達すると予測されます。パンデミック後の回復が進んでいることを考慮し、化学療法分野の成長率は、今後8年間のCAGRを5%に修正しました。

米国市場は43億米ドル、中国はCAGR4.8%の成長予測

米国の婦人科領域のがん治療薬市場は、2022年には43億米ドルに達すると推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが4.8％となり、2030年には38億米ドルの市場規模に達すると予測されます。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ5％と4.1％の成長が予測されています。欧州では、ドイツがCAGR4.2%で成長すると予測されています。

調査対象企業の例

• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Sanofi SA
• Takeda Pharmaceutical Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• 世界のその他の地域

第4章 競合

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Gynecological Cancer Drugs Market to Reach $21.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Gynecological Cancer Drugs estimated at US$14.4 Billion in the year 2022, is projected to reach a revised size of US$21.5 Billion by 2030, growing at aCAGR of 5.2% over the period 2022-2030. Targeted Therapy, one of the segments analyzed in the report, is projected to record 5.6% CAGR and reach US$10.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chemotherapy segment is readjusted to a revised 5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $4.3 Billion, While China is Forecast to Grow at 4.8% CAGR

The Gynecological Cancer Drugs market in the U.S. is estimated at US$4.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Select Competitors (Total 43 Featured) -

• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Sanofi SA
• Takeda Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Gynaecological Cancer Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 3: World 16-Year Perspective for Cervical Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Uterine Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Uterine Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 6: World 16-Year Perspective for Uterine Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 7: World Gynecological Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Gynecological Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 10: World 16-Year Perspective for Gynecological Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 13: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 16: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 19: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 22: World 16-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Vaginal & Vulvar Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Vaginal & Vulvar Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 25: World 16-Year Perspective for Vaginal & Vulvar Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• JAPAN
  • Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• CHINA
  • Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 46: China 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 49: China 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• EUROPE
  • Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Gynecological Cancer Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Gynecological Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• FRANCE
  • Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 61: France 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 64: France 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• GERMANY
  • Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• UNITED KINGDOM
  • Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• REST OF EUROPE
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 85: Rest of Europe 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 87: Rest of Europe Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 88: Rest of Europe 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• ASIA-PACIFIC
  • Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 91: Asia-Pacific 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 94: Asia-Pacific 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030
• REST OF WORLD
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 97: Rest of World 16-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2014, 2023 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 99: Rest of World Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 100: Rest of World 16-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2014, 2023 & 2030

IV. COMPETITION